Impax Agrees to Pay $35M to Partially Settle Acne Drug Complaint

Impax Laboratories Inc. has agreed to pay $35 million to settle antitrust claims with a class of people who bought its blockbuster acne drug Solodyn, bringing a portion of its four-year litigation to a close.

A jury trial began March 12 in which Impax is mounting a defense against big pharmacy chains like CVS Health Corp. and Walgreens Boots Alliance Inc. That class, separate from the customers who paid cash for Solodyn, alleges that Impax illegally agreed with Medicis Pharmaceutical Corp. to thwart competition by agreeing to delay a generic version of the acne drug.

Impax is the last defendant ...